Evidence map›Paper›PMID 38010407›Full record

ArticleAnnals of hematology2024

Warm autoimmune hemolytic anemia associated with SARS-CoV-2 infection responsive to eculizumab.

Yuemin Gong, Xinyu Zhang, Xiaoyu Chen, Hui Yang, Yawen Zhang, Guangsheng He, Jianyong Li

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yuemin GongDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Key Laboratory of Hematology of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalized Medicine, No. 300 Guangzhou Road, Nanjing, 210000, China.
Xinyu ZhangDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Key Laboratory of Hematology of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalized Medicine, No. 300 Guangzhou Road, Nanjing, 210000, China.
Xiaoyu ChenDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Key Laboratory of Hematology of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalized Medicine, No. 300 Guangzhou Road, Nanjing, 210000, China.
Hui YangDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Key Laboratory of Hematology of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalized Medicine, No. 300 Guangzhou Road, Nanjing, 210000, China.
Yawen ZhangDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Key Laboratory of Hematology of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalized Medicine, No. 300 Guangzhou Road, Nanjing, 210000, China.
Guangsheng HeDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Key Laboratory of Hematology of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalized Medicine, No. 300 Guangzhou Road, Nanjing, 210000, China. heguangsheng1972@sina.com.ORCID http://orcid.org/0000-0002-3944-5897
Jianyong LiDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Key Laboratory of Hematology of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalized Medicine, No. 300 Guangzhou Road, Nanjing, 210000, China.
Jiangsu Province Hospital · CN

Funding

National Natural Science Foundation of China 81900109
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anemia, Hemolytic, AutoimmuneCOVID-19Antibodies, Monoclonal, HumanizedHumansSARS-CoV-2Antibodies, Monoclonal, Humanizedeculizumab

Identifiers

PMID38010407
OpenAlexW4389053065

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.